Dementia‐related adverse events in PARADIGM‐HF and other trials in heart failure with reduced ejection fraction

AIMS: Inhibition of neprilysin, an enzyme degrading natriuretic and other vasoactive peptides, is beneficial in heart failure with reduced ejection fraction (HFrEF), as shown in PARADIGM‐HF which compared the angiotensin receptor–neprilysin inhibitor (ARNI) sacubitril/valsartan with enalapril. As ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Cannon, Jane A., Shen, Li, Jhund, Pardeep S., Kristensen, Søren L., Køber, Lars, Chen, Fabian, Gong, Jianjian, Lefkowitz, Martin P., Rouleau, Jean L., Shi, Victor C., Swedberg, Karl, Zile, Michael R., Solomon, Scott D., Packer, Milton, McMurray, John J.V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2016
Materias:
Medical Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5248626/
https://www.ncbi.nlm.nih.gov/pubmed/27868321
http://dx.doi.org/10.1002/ejhf.687

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5248626/
https://www.ncbi.nlm.nih.gov/pubmed/27868321
http://dx.doi.org/10.1002/ejhf.687

Ejemplares similares